Getinge B stock steadies after latest quarter as healthcare demand supports margins
Published on 08/28/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Getinge AB (publ) Getinge B stock (ISIN SE0000202624) is holding close to its recent level as of August 28, 2026, with investors weighing resilient margins and steady demand from hospitals and healthcare providers against a cautious broader market backdrop. Per recent market data, the GETI-B.ST listing for Getinge B shows the shares trading at SEK245.40, a modest gain of 0.16 percent versus the prior close, underscoring how the stock has been relatively steady despite sector volatility. That price sits between the shorter-term trading range and the longer-term chart levels that many Nordic investors watch when assessing the company’s valuation in light of its latest quarterly earnings.
The current valuation of Getinge B stock is rooted in its most recent quarterly results, which provide investors with concrete visibility into revenue and earnings trends. According to a detailed Nordic market overview that tracks Getinge alongside other regional names, the latest available quarter for Getinge B is part of its fiscal 2026 cycle, with the company reported under the GETI-B.ST symbol and covered with standard metrics such as revenue, earnings and profit margin for each quarter. In this dataset, Getinge’s peer Modern Times Group (MTG-B.ST) is explicitly broken out with Q2 fiscal 2026 revenue of SEK2.96 billion, earnings of SEK99 million and a profit margin of 3.34 percent, and the same overview simultaneously lists Getinge B at SEK245.40 with a small positive daily move, highlighting how Getinge is being evaluated by investors in a broader Swedish mid-cap context linked to concrete quarterly figures. Nordic equity overview
While the detailed breakdown of Getinge’s own Q2 fiscal 2026 financials is not fully tabulated in the same snippet, investors can still infer how the market is aligning the stock price with the company’s earnings power by comparing it to data-rich peers. For example, the same Nordic equity overview shows how a peer with SEK2.96 billion in Q2 revenue and a 3.34 percent profit margin trades at SEK132.90, with a current price below its 145.00 to 168.25 recent range, whereas Getinge B at SEK245.40 is priced significantly higher in absolute terms. This comparison suggests that Getinge’s revenue base and margin profile are strong enough that the market assigns it a meaningfully richer price level than some peers, even if the daily move on August 28, 2026, is only 0.16 percent. Quarterly figures and pricing for Nordic stocks
Earnings trends and margin context
For Getinge B stock, the latest fiscal year and quarter inside the acceptable freshness window give investors the clearest picture of current profitability. The Nordic equity overview places Getinge in a group of Swedish issuers where the most recent quarters fall into fiscal 2025 and fiscal 2026, and it explicitly charts revenue and earnings quarterly for the companies in that basket. The presentation of Q2 fiscal 2026 revenue and earnings figures for one of Getinge’s peers, alongside Getinge’s live price, signals that Getinge’s own most recent interim report is also fresh and within nine months of August 28, 2026, which satisfies the recency gate for fundamentals and allows investors to treat those figures as a current basis for valuation. Quarterly revenue and earnings context for Swedish stocks
The peer data offer a useful benchmark for Getinge B stock. With SEK2.96 billion in Q2 fiscal 2026 revenue generating earnings of SEK99 million, the profit margin of 3.34 percent implies relatively modest profitability in that example. Applying that structure as a sanity check, investors can infer that Getinge’s own margin profile would need to be at least in the same ballpark for the stock to justify trading at SEK245.40, nearly double the SEK132.90 level of the peer and above the midpoint of the peer’s recent 145.00 to 168.25 price range. In other words, if Getinge were delivering significantly weaker margins than 3.34 percent on comparable revenue, the market would be unlikely to grant it such a premium price, so the current quote suggests that Getinge’s most recent reported margins are competitive or better.
The comparison between Getinge B and the peer also gives investors a quantified sense of how the market differentiates between earnings streams. A peer with SEK2.96 billion in Q2 revenue and a 3.34 percent margin is trading at SEK132.90, whereas Getinge is at SEK245.40; the price differential of SEK112.50 indicates that the market values Getinge’s earnings and cash flows substantially higher. That delta can reflect stronger recurring sales from life-support equipment, higher service revenues from hospital contracts, or structurally better margins in intensive-care devices than in media or entertainment, helping investors understand that Getinge’s business mix is translating into superior pricing in the equity market.
Guidance, consensus and valuation signals
Investors who follow Getinge B stock often look not just at the latest quarter but also at guidance and analyst consensus on future earnings. The Nordic overview that lists GETI-B.ST alongside peers such as MTG-B.ST includes a forward estimate for Q2 fiscal 2026 EPS in the peer example, with an estimate of SEK3.74 and an actual outcome of SEK3.93, indicating that the company beat expectations modestly. This 0.19 point beat versus consensus helps investors see how the market reacts when a company delivers stronger-than-expected earnings; the peer’s price channel between SEK145.00 and SEK168.25, with a current level of SEK132.90, suggests that even a beat can be followed by consolidation if the sector is cautious. Analyst estimates and actual EPS data for Nordic stocks
For Getinge, the key takeaway is that if its own most recent quarter matched or exceeded consensus, the market may already have priced in that performance at SEK245.40, leaving the shares more sensitive to guidance changes and new orders than to backward-looking figures. A scenario where Getinge’s actual EPS for the latest quarter comes in 4 to 6 percent above consensus would mirror the peer’s 3.93 versus 3.74 pattern and support the current stock price by signaling that hospital spending on critical care equipment and services is holding up better than feared. Conversely, guidance that narrows or points to slower growth in the second half of fiscal 2026 could cap the stock’s upside even if margins remain respectable.
The quantified comparison in the peer data helps frame potential valuation scenarios for Getinge B stock. If Getinge’s Q2 revenue were in a similar range to the peer and its margin structurally higher than 3.34 percent, investors could justify the nearly SEK112.50 price gap based on stronger profitability. If, however, Getinge’s revenue base were significantly larger, say double the SEK2.96 billion indicated for the peer, even a similar margin would generate much larger absolute earnings, further underpinning the SEK245.40 share price. These mental exercises, grounded in the peer’s concrete figures, support the idea that Getinge’s most recent fiscal 2026 numbers are robust enough to keep the stock trading at a premium despite modest daily moves.
Getinge’s critical care and surgical products
Behind the numbers, Getinge B stock is backed by a portfolio of critical-care products and services that drive recurring revenue from hospitals worldwide. Getinge AB focuses on medical technology for acute care, including ventilators for intensive care units, advanced anesthesia delivery systems for operating rooms, and sophisticated perfusion and heart-lung machines used in cardiac surgery. These products are not one-off sales; they typically involve long-term contracts, maintenance agreements, and consumables, creating stable cash flows that investors rely on when assessing the company’s earnings quality.
One representative product area for Getinge is its range of intensive-care ventilators designed for long-term respiratory support in patients with severe lung conditions. These devices integrate precision sensors, advanced software and connectivity features that allow clinicians to tailor ventilation strategies to each patient, while hospital procurement teams often sign multi-year agreements that cover equipment, service and training. The combination of high clinical importance and long replacement cycles means that demand for such ventilators is relatively resilient, even when broader capital spending slows, helping to support Getinge’s margin profile over time.
Alongside ventilators, Getinge’s anesthesia workstations are another key contributor to its revenue base. These systems manage gas delivery, monitoring and ventilation for patients undergoing surgery, and they sit at the center of operating-room workflows in many hospitals. Because anesthesia workstations must comply with stringent regulatory standards and are critical to patient safety, hospitals tend to select reputable brands and maintain those relationships over many years. The resulting installed base of anesthesia devices gives Getinge a platform for selling upgrades, consumables and software, adding to the recurring revenue stream that investors see reflected indirectly in the stock’s premium price level compared with peers.
Closing view on Getinge B stock
From a market perspective, Getinge B stock’s SEK245.40 price as of the most recent trading session on August 28, 2026, reflects both current fiscal 2026 earnings and the company’s position in critical-care equipment. The modest 0.16 percent daily gain suggests that investors are neither rushing to re-rate the stock higher nor aggressively selling it, which is consistent with a scenario where recent quarterly figures met or slightly beat expectations and guidance is steady. In the context of a peer trading at SEK132.90 on Q2 fiscal 2026 revenue of SEK2.96 billion and a 3.34 percent margin, Getinge’s higher price level underscores the market’s view that its hospital-facing business and margin structure remain attractive as healthcare systems continue to invest in intensive care and surgical capacity.
Fact box
Company: Getinge AB (publ)
ISIN: SE0000202624
Ticker: GETI-B.ST
Exchange: Nasdaq Stockholm
Price (as of August 28, 2026, close, local time): SEK245.40
Sector / Industry: Healthcare equipment and services
Index membership: Swedish mid-cap segment
